Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

Abstract Respiratory pandemics like COVID-19 continued to strain healthcare systems worldwide. Numerous antiviral, antimalarial, and anti-inflammatory treatments were administered to many patients to pursue effective therapeutics. This study aims to assess the efficacy of the anti-inflammatory agent...

Full description

Saved in:
Bibliographic Details
Main Authors: Abbas Al Mutair, Saad Alhumaid, Gasmelseed Y. Ahmad, Ali A. Rabaan, Sameer A. Alkubati, Hamdan Albaqawi, Awatif M. Alrasheeday, Bushra Alshammari, Kawther Alsaleh, Richard Mottershead, Muhammad Daniyal, Awad Al-Omari
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Tocilizumab
Respiratory illness
Saudi Arabia
COVID-19
Efficacy
Mortality
Online Access:https://doi.org/10.1038/s41598-025-08638-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-08638-3

Similar Items